| Yin, Jun |
CA209-6KP, NCT05213312: Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC |
|
|
| Recruiting | 2/3 | 90 | RoW | Nivolumab, Cisplatin, Paclitaxel, 5Fluorouracil, Esophagectomy (minimally invasive) | Shanghai Zhongshan Hospital, Bristol-Myers Squibb | Esophageal Squamous Cell Carcinoma | 11/22 | 03/24 | | |
| Zhou, Jian |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT06507436: The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery |
|
|
| Recruiting | 3 | 101 | RoW | Herombopag tablets, Herombopag placebo tablets | Jiangsu HengRui Medicine Co., Ltd. | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | 08/25 | 09/25 | | |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies |
|
|
| Recruiting | 2 | 60 | RoW | SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 12/25 | 06/26 | | |
NCT06778031: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 54 | RoW | SHR-A1811, SHR-1316, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 06/28 | 09/28 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT06178809: Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 475 | RoW | | Singlera Genomics Inc., Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 04/25 | 12/25 | | |
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers |
|
|
| Completed | N/A | 2430 | RoW | | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc. | Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 06/23 | 07/23 | | |
| Ge, Junbo |
NCT03008083: Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation |
|
|
| Recruiting | 4 | 2446 | RoW | 3 months DAPT, Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day), 12 months DAPT | Shanghai MicroPort Medical (Group) Co., Ltd. | Drug-Eluting Stents, Percutaneous Coronary Intervention | 12/20 | 10/22 | | |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/26 | 06/30 | | |
NCT05260411: A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia |
|
|
| Recruiting | 3 | 240 | RoW | AK102, Placebo | Akeso | Hyperlipidemia | 06/22 | 12/22 | | |
| Active, not recruiting | 2 | 100 | RoW | Pirfenidone Oral Capsule, Placebo Oral Capsule | Shanghai Zhongshan Hospital, Beijing Continent Pharmaceutical Co, Ltd. | Myocardial Fibrosis | 05/24 | 06/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
NCT03466918: China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population |
|
|
| Active, not recruiting | N/A | 58 | RoW | SAPIEN 3 THV with the Commander delivery system | Edwards Lifesciences | Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation | 07/19 | 09/25 | | |
NCT04582877: Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial |
|
|
| Completed | N/A | 300 | RoW | FFR measurement | Zurich Medical Inc. | Myocardial Ischemia | 11/23 | 04/24 | | |
NCT03716011: A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT |
|
|
| Not yet recruiting | N/A | 2700 | RoW | EXCROSSAL | JW Medical Systems Ltd | Coronary Artery Disease | 12/21 | 12/25 | | |
NCT04414878: VitaFlowâ„¢ II Transcatheter Aortic Valve System Pre-market Trial |
|
|
| Recruiting | N/A | 145 | RoW | VitaFlowâ„¢ II Transcatheter Aortic Valve System | Shanghai MicroPort CardioFlow Medtech Co., Ltd. | Aortic Stenosis | 01/22 | 01/27 | | |
NCT06110988: A Clinical Study for the Pan-vascular Interventional Robotic System |
|
|
| Not yet recruiting | N/A | 5 | RoW | Pan-vascular interventional robotic system | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention, Pan-vascular Interventional Robotic System | 09/24 | 09/24 | | |
NCT03736226: A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China |
|
|
| Active, not recruiting | N/A | 2000 | RoW | SYNERGYTM Stent System | Boston Scientific Corporation | Cardiovascular Diseases | 08/24 | 03/28 | | |
NCT06502938: A Clinical Trial Evaluating the Pan-vascular Interventional Robotic System for Panvascularization Interventional Surgery |
|
|
| Not yet recruiting | N/A | 159 | RoW | Pan-vascular interventional robotic system, Traditional artificial percutaneous coronary intervention | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention | 07/25 | 12/25 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
NCT06032572: Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) |
|
|
| Not yet recruiting | N/A | 204 | RoW | VRS100 robotic-assisted PCI, Manual PCI | Shenzhen Raysight Intelligent Medical Technology Co., Ltd., Shanghai Zhongshan Hospital, West China Hospital, Shenzhen People's Hospital | Coronary Artery Disease, Cardiovascular Diseases, Coronary Disease, Myocardial Ischemia, Arteriosclerosis, Vascular Disease Occlusive | 08/24 | 08/24 | | |
VITAL, NCT05813704: Coronary Crossing System in Patients With Coronary Chronic Total Occlusions |
|
|
| Recruiting | N/A | 156 | RoW | Coronary Crossing System of Shanghai MicroPort Rhythm | Shanghai MicroPort Rhythm MedTech Co., Ltd., Shanghai Zhongshan Hospital, Xiamen Cardiovascular Hospital, Xiamen University, Shanghai Baoshan District Wusong Central Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Wenzhou Medical University, Tianjin First Central Hospital, The Affiliated Hospital Of Southwest Medical University, Hebei General Hospital, West China Hospital, First Affiliated Hospital of Army Medical University, PLA, Lanzhou University First Hospital, Nanfang Hospital, Southern Medical University, The Second Affiliated Hospital of Dalian Medical University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Chronic Total Occlusion of Coronary Artery | 04/25 | 05/25 | | |
NCT05947448: Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study |
|
|
| Recruiting | N/A | 1215 | RoW | Azilsartan Medoxomil Potassium Tablet, Nifedipine Sustained -release Tablets, Levoamlodipine Maleate Table | Hasten Biopharmaceutical Co., Ltd. | Essential Hypertension | 06/25 | 12/25 | | |
| Yuan, Wei Tang |
NCT05901480: An Investigator Initiated Study for OTOV101N+OTOV101C Injection |
|
|
| Recruiting | N/A | 25 | RoW | OTOV101N+OTOV101C Injections | Otovia Therapeutics | DFNB9 | 12/24 | 02/25 | | |
| Wang, Zheng |
NCT06387368: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer |
|
|
| Not yet recruiting | 4 | 488 | NA | Huaier Granule, Z20000109#NMPA Approval Number#, Capecitabine, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Non-resectable | 03/28 | 08/28 | | |
NCT06368063: The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer |
|
|
| Recruiting | 4 | 642 | RoW | Huaier granule, Z20000109#NMPA Approval Number#, chemotherapy drugs, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Resectable | 03/26 | 03/28 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
| Recruiting | 2 | 116 | RoW | Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 12/25 | 06/26 | | |
NCT05229133: Efficacy and Safety of CLEAR in Myopia and Astigmatism in Chinese Population |
|
|
| Recruiting | N/A | 215 | RoW | CLEAR, Corneal lenticule extraction for advanced refractive correction | Ziemer Ophthalmic Systems AG, Tigermed Consulting Co., Ltd | Myopic Astigmatism | 03/23 | 03/23 | | |
| Tan, Lijie |
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
|
|
| Recruiting | 3 | 426 | RoW | Camrelizumab, radiotherapy | Zhigang Li, Jiangsu HengRui Medicine Co., Ltd. | Resectable Esophageal Squamous Cell Carcinoma | 12/28 | 12/30 | | |
| Li, Xiaoying |
NCT05816057: A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 476 | RoW | semaglutide injection | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Diabetes Mellitus, Type 2 | 07/23 | 10/23 | | |
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea |
|
|
| Completed | 3 | 469 | Europe, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Sleep Apnea, Obesity | 03/24 | 03/24 | | |
NCT05834868: Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes |
|
|
| Recruiting | 3 | 805 | RoW | THDB0206 Injection, Insulin Lispro Injection | Tonghua Dongbao Pharmaceutical Co.,Ltd | Type 2 Diabetes | 03/24 | 10/24 | | |
NCT06396429: To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese |
|
|
| Recruiting | 3 | 540 | RoW | HRS9531 injection, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity | 07/25 | 08/25 | | |
NCT05680129: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM |
|
|
| Active, not recruiting | 3 | 623 | RoW | Ecnoglutide high dosage, XW003, Ecnoglutide low dosage, Dulaglutide, Metformin | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05702073: To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin. |
|
|
| Recruiting | 3 | 400 | RoW | INS068 injection, Insulin Glargine | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05881837: Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes |
|
|
| Active, not recruiting | 2 | 249 | RoW | HRS9531 injection, HRS9531 injection Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity | 10/24 | 10/24 | | |
| Not yet recruiting | 2 | 180 | NA | HDM1002 100 mg QD, HDM1002, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks, Placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Overweight and Obesity | 10/24 | 11/24 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
NCT05516966: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 64 | RoW | HRS9531, Placebo, Dulaglutide Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
NCT06520540: HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects |
|
|
| Not yet recruiting | 1 | 72 | RoW | HDM1002 100 mg QD 12weeks, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks，Q 2W for titration, HDM1002 400 mg QD 12weeks，Q 3W for titration, Placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Glucagon-Like Peptide-1 Receptor Agonists | 11/24 | 12/24 | | |
NCT06427642: Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases |
|
|
| Recruiting | N/A | 120 | RoW | Mononuclear cells, Mild hypothermia therapy, Breathing support technique, Total parenteral nutrition | Shandong Qilu Stem Cells Engineering Co., Ltd., Qilu Children's Hospital of Shandong University | Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia, Short Bowel Syndrome | 05/24 | 04/25 | | |
| Zhong, Ming |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
NCT04468529: Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 154 | RoW | Recombinant human Neuregulin for injection, Neucardin, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 04/22 | 04/24 | | |
| Liu, Peng |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
NCT05316246: Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 40 | NA | Brentuximab Vedotin in Combination with Tislelizumab | Shanghai Zhongshan Hospital, Takeda, BeiGene | NK/T Cell Lymphoma Nos | 06/24 | 12/24 | | |
NCT05436223: Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 100 | RoW | Human CD19Targeted T Cells Injection, CD19 CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Zhongshan Hospital | B-cell Non-Hodgkin's Lymphoma | 08/24 | 08/26 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT03720457: Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. |
|
|
| Recruiting | 1 | 18 | RoW | Human CD19 targeted T Cells Injection | Hrain Biotechnology Co., Ltd., Shanghai Zhongshan Hospital | CD19-positive, Diffuse Large B-cell Lymphoma, Follicular Lymphoma | 10/21 | 10/23 | | |
| Recruiting | 1 | 57 | RoW | TQB3473 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Hematological Malignancies | 12/21 | 06/22 | | |
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
| Recruiting | 1 | 140 | RoW | TQB2934 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Multiple Myeloma | 10/24 | 10/25 | | |
NCT06700395: A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma |
|
|
| Recruiting | 1 | 136 | RoW | TQB2029 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Multiple Myeloma | 03/26 | 03/28 | | |
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia |
|
|
| Completed | 1 | 46 | US, RoW | APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Ascentage Pharma Group Inc. | Waldenstrom Macroglobulinemia | 02/24 | 02/24 | | |
| Zhang, Lei |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
NCT05888870: ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor |
|
|
| Recruiting | 4 | 50 | RoW | SCT800 and Daratumumab, Immune tolerance induction combine anti-CD38, SCT800, Immune tolerance induction only | Institute of Hematology & Blood Diseases Hospital, China, Sinocelltech Ltd. | Hemophilia A With Inhibitor | 12/26 | 12/26 | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT05487976: Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor |
|
|
| Recruiting | 3 | 50 | RoW | Recombinant human activated coagulation factor VII for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hemophilia A, Hemophilia B | 04/23 | 04/23 | | |
| Active, not recruiting | 3 | 194 | Europe, Canada, Japan, US, RoW | Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo | Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc. | Immune Thrombocytopenia | 06/25 | 11/26 | | |
NCT06297655: A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A |
|
|
| Not yet recruiting | 3 | 60 | RoW | Recombinant human activated coagulation factor VIII for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Hemophilia A | 04/25 | 04/25 | | |
NCT05203679: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug |
|
|
| Active, not recruiting | 3 | 32 | RoW | Single dose intravenous injection of BBM-H901 | Shanghai Belief-Delivery BioMed Co., Ltd | Hemophilia B | 04/24 | 06/28 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05619926: Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor |
|
|
| Completed | 2 | 32 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing Novikang Medical Technology Co., LTD | Hemophilia | 08/23 | 08/23 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Recruiting | 2 | 25 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 02/25 | 02/25 | | |
NCT06552429: Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET |
|
|
| Recruiting | 2 | 27 | RoW | Peginterferon α-2b injection | Xiamen Amoytop Biotech Co., Ltd. | Essential Thrombocythemia | 09/25 | 09/27 | | |
NCT06594146: Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) |
|
|
| Not yet recruiting | 2 | 60 | NA | CM313 injection, placebo | Keymed Biosciences Co.Ltd | Primary Immune Thrombocytopenia | 12/25 | 12/25 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT05027230: A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor |
|
|
| Completed | 1/2 | 77 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 07/23 | 07/23 | | |
NCT06111638: Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs |
|
|
| Recruiting | 1/2 | 12 | RoW | Single dose intravenous injection of BBM-H803 | Shanghai Belief-Delivery BioMed Co., Ltd, Shanghai MYGT Biopharmaceutical LLC | Hemophilia A | 06/26 | 06/30 | | |
NCT04747964: A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor |
|
|
| Completed | 1 | 16 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 04/21 | 04/21 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
| Recruiting | 1 | 108 | RoW | GLB-001, GLB-C183-A-2 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy | 12/26 | 12/27 | | |
NCT05217459: The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease |
|
|
| Completed | N/A | 128 | RoW | Self-expanding intracranial drug stent system | Sinomed Neurovita Technology Inc., Changhai Hospital | Intracranial Arterial Diseases, Stent Restenosis, Percutaneous Transluminal Angioplasty | 08/23 | 03/24 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
| Completed | N/A | 34 | US, RoW | SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System | Boston Scientific Corporation | Pancreatic Diseases, Bile Duct Diseases, Hepatic Disease | 12/24 | 01/25 | | |
NCT05442528: Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study |
|
|
| Not yet recruiting | N/A | 20 | NA | | Shanghai Vitalgen BioPharma Co., Ltd. | Hemophilia B | 12/24 | 12/24 | | |
| Xu, Bo |
| Active, not recruiting | N/A | 431 | RoW | study group, BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System, control group, Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V® | Shanghai Bio-heart Biological Technology Co., Ltd., CCRF Inc., Beijing, China | Coronary Artery Disease, Antineoplastic Agents | 08/20 | 08/24 | | |
| Active, not recruiting | N/A | 430 | RoW | Firesorb, XIENCE | Shanghai MicroPort Medical (Group) Co., Ltd. | Coronary Artery Disease | 10/20 | 10/24 | | |
IRONMAN-III, NCT05205499: A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease |
|
|
| Active, not recruiting | N/A | 1059 | RoW | Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System | Biotyx Medical (Shenzhen) Co., Ltd. | Coronary Artery Disease | 08/24 | 08/28 | | |
| ZHANG, Xin |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
